Asset partnering
Velocin plans to out-license vaccine candidates to pharmaceutical partners after Phase I, generating revenue from upfront payments, development milestones, and sales royalties, starting from enterovirus.
Contact
Get in touch
Velocin compounds value across pathogens: public funding reduces development risk, and asset partnerships generate revenue.
Grants and public funding
CEPI, Gavi, BARDA, the Gates Foundation, and HERA can fund preclinical and clinical development, providing non-dilutive capital that reduces technical risk before partnering.
Write to us
Email address to be confirmed (placeholder). Velocin will publish its contact address here before launch.